Hypertensive Label Changes Could Remedy Under-Treatment Problem -Cmte
Executive Summary
More explicit dosing instructions in labeling might be the best way to urge physicians to more aggressively manage the under-treated hypertensive population, FDA's Cardio-Renal Advisory Committee said at an April 18 meeting to review a first-line claim for Bristol-Myers Squibb's Avalide
You may also be interested in...
Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy
Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance
Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy
Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance
ARB Marketers May Be Tense After AHRQ Comparative Effectiveness Report
A comparative effectiveness review from the Agency for Healthcare Research and Quality comparing ACE inhibitors and ARBs may create challenges for brand manufacturers in formulary negotiations